Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

Table 1 Outcomes, health effects and discounted costs for the baseline and QIV strategy

	Baseline	Scenario: QIV switch for 6 m-5yo
	Baseline	New situation	Difference
Clinical influenza B outcomes (per season)
Total number of symptomatic cases	6,564,965	6,158,397	−406,569
Total number outpatient visits	2,341,626	2,188,848	− 152,778
Total number of hospitalizations	189,677	178,359	−11,318
Total number of deaths	6596	6203	− 393
Health effects related to influenza B (per season)
Total QALYs lost because of influenza illness	61,646	57,902	− 3744
Total QALYs lost because of influenza-related deaths	47,861	45,304	− 2556
Total life-years lost because of influenza-related deaths	63,711	60,313	− 3398
Discounted costs (R$)
Vaccination	687,307,209	863,977,370	176,670,161
Outpatient visit	92,744,270	87,410,202	−5,334,068
Hospitalized	196,767,867	186,295,892	−10,471,974
Death	20,417,936	19,332,171	−1,085,765
Productivity losses	1,351,536,346	1,278,078,007	− 73,458,340

Results are averaged over the 7 seasons considered. Only influenza B outcomes are considered since the switch to QIV only affects influenza B cases. Costs are discounted at 5% per year

ISSN: 1471-2458